Department of Microbiology and Immunology, Center for AIDS Research, and Children's Research Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Department of Pediatrics, Weill Cornell Medicine/ New York Presbyterian, New York, New York, USA.
Immunol Rev. 2022 Aug;309(1):90-96. doi: 10.1111/imr.13108. Epub 2022 Jul 7.
The SARS-CoV-2 pandemic has resulted in unprecedented health and economic losses. Children generally present with less severe disease from this virus compared with adults, yet neonates and children with COVID-19 can require hospitalization, and older children can develop severe complications, such as the multisystem inflammatory syndrome, resulting in >1500 deaths in children from COVID-19 since the onset of the pandemic. The introduction of effective SARS-CoV-2 vaccines in school-age children and adult populations combined with the emergence of new, more highly transmissible SARS-CoV-2 variants has resulted in a proportional increase of infections in young children. Here, we discuss (1) the current knowledge on pediatric SARS-CoV-2 infection and pathogenesis in comparison with adults, (2) the data on vaccine immunogenicity and efficacy in children, and (3) the benefits of early life SARS-CoV-2 vaccination.
SARS-CoV-2 大流行造成了前所未有的健康和经济损失。与成年人相比,儿童通常感染这种病毒的症状较轻,但新生儿和 COVID-19 患儿可能需要住院治疗,年龄较大的儿童可能会出现严重并发症,如多系统炎症综合征,自大流行开始以来,已有超过 1500 名儿童死于 COVID-19。有效 SARS-CoV-2 疫苗在学龄儿童和成年人群中的引入,加上新的、传播性更强的 SARS-CoV-2 变异体的出现,导致幼儿感染的比例增加。在这里,我们讨论了(1)与成年人相比,目前关于儿童 SARS-CoV-2 感染和发病机制的知识,(2)儿童疫苗免疫原性和疗效的数据,以及(3)早期 SARS-CoV-2 疫苗接种的益处。